Antonio Spanevello, CHEST 2022: An Update on Recent Therapeutics in Asthma
Asthma is a chronic heterogenous disease, airway eosinophilic inflammation can be reduced with biologics; however, there remains many unmet needs in the treatment of type-2 low severe asthma. It was a pleasure to talk with our editorial board member, Prof. Antonio Spanevello (University of Insubria and Maugeri Care and Research Institute, IRCCS Tradate, Varese, Italy) to learn more around the latest updates in asthma treatment, including the phase 2 and 3 trials surrounding risankizumab and tezepelumab in severe asthma and the most promising targets under investigation.
‘Biologics in non eosinophilic asthma’ was presented at CHEST Congress 2022, 27-29 June 2022.
- Why do you think that risankizumab failed to show a clinical benefit in patients with severe asthma, and what does this mean for current and future research targeting cytokines? (0:29)
- Could you tell us a little about tezepelumab and the findings of the NAVIGATOR and PATHWAY clinical trials? (2:21)
- Which emerging molecular targets do you consider promising? (3:52)
Disclosures: Antonio Spanevello discloses consulting for GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini; receiving grant/ research support from GSK and Chiesi; serving on advisory boards for GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini; and receiving honoraria from GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
Share this Video
Related Videos In Asthma
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!